Original research
by
Oviedo-Joekes, Eugenia et al
Release Date
2019
Geography
Canada
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this induction phase.
Findings/Key points
With data from 3 Canadian studies, encompassing a total of 2993 induction injections, there were only 5 related opioid overdoses that required naloxone (4 with DAM, 1 with HDM). As expected, the rate per injection day was higher for adverse events and severe adverse events during induction compared to after induction. However, all overdose events were safely treated onsite and there were no deaths or other lasting sequelae of these events. These data confirm the overall safety of iOAT during both induction and later treatment.
Design/methods
Data from 2 clinical trials and one cohort study
Keywords
Clinical guidance
Evidence base
Harm reduction
Safer supply
About prescribers
Outcomes
Substitution/OAT
Injecting drugs
